查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1591734

抗生素抗性市場:現狀分析與預測(2024年～2032年)

Antibiotic Resistance Market: Current Analysis and Forecast (2024-2032)
出版日期: | 出版商: UnivDatos Market Insights Pvt Ltd | 英文 146 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

由於研發活動的增加，抗生素抗藥性市場預計將以 5.4% 左右的速度穩定成長。例如，2022年11月啟動了抗菌素抗藥性多利益相關者夥伴關係平台，以應對全球日益增長的抗菌素抗藥性威脅和影響。聯合國糧食及農業組織（FAO）、聯合國環境規劃署（UNEP）、世界衛生組織（WHO）和世界動物衛生組織（WOAH）加入了這項名為四方會議的倡議，以強調抗生素抗藥性對人類、動物、植物、生態系統和生計的威脅。此外，抗生素抗藥性感染病例的增加和抗生素研發活動的投資增加正在推動抗生素抗藥性市場的發展。

依疾病類型，市場分為泌尿道感染、腹腔內感染、血流感染、艱難梭菌感染等。預計泌尿道感染 (UTI) 領域將在 2023 年佔據市場的大部分佔有率，這是由於 UTI 的發病率不斷增加，尤其是在女性、老年人和患有慢性疾病的人群中。隨著大腸桿菌等抗生素抗藥性菌株的出現頻率不斷增加，傳統治療方法變得越來越無效，新型抗生素和其他治療方法的市場正在蓬勃發展。由於這些感染對於許多醫療保健提供者來說難以管理，因此他們更加重視開發特定的治療、診斷和預防方法。此外，人們對抗生素抗藥性後果的認識不斷提高，正在推動泌尿結石的治療的努力和資金投入。在該領域，需要開發有效的治療方法並加強控制措施，以對抗抗生素抗藥性細菌的增加，特別是在泌尿結石中，並期待利益相關者做出積極的努力。

依病原體類型，市場分為鮑曼不動桿菌、綠膿桿菌、金黃色葡萄球菌、肺炎鏈球菌和其他。預計金黃色葡萄球菌部分將在預測期內顯著增長，因為耐甲氧西林金黃色葡萄球菌 (MRSA) 和甲氧西林敏感菌株引起的感染正在對其他類別的抗生素產生抗藥性。金黃色葡萄球菌是一種引起醫院相關和社區獲得性皮膚感染、肺炎、菌血症和其他感染的病原體，因此需要有效的治療。新的抗藥性細菌的出現要求製藥公司開發針對這些抗藥性細菌的新抗生素，以及新的治療方法，包括單株抗體和噬菌體療法。因此，預計在預測期內，金黃色葡萄球菌將在病原體類型中呈現顯著的成長率。

依藥物類別，市場分為噁唑烷酮類、脂糖肽類、四環素類及其他類。由於多重抗藥性革蘭氏陽性菌感染（尤其是抗甲氧西林金黃色葡萄球菌 (MRSA) 和耐萬古黴素腸球菌 (VRE)）的增加，預計噁唑烷酮類藥物在預測期內將顯著增長。在噁唑烷酮類抗生素中，利奈唑胺和特地唑胺具有抑制細菌蛋白質合成的新途徑，使其成為治療這些難以治療的感染的有價值的治療藥物。傳統抗生素抗藥性的上升促使噁唑烷酮類抗生素等新一代抗生素進入全球市場。此外，噁唑烷酮抗生素在臨床環境中的使用日益增多以及不斷努力開發噁唑烷酮抗生素新化合物市場也在推動這一市場的發展。噁唑烷酮市場有可能使用戶能夠獲得針對抗藥性感染的有效治療，從而在治療醫療機構的抗生素抗藥性和最大限度改善患者健康方面發揮重要作用。因此，預計預測期內按藥物類別劃分的噁唑烷酮將出現顯著增長。

為了更了解抗生素抗藥性的市場採用情況，根據北美（美國、加拿大和北美其他地區）、歐洲（德國、英國、法國、西班牙、義大利和歐洲其他地區）、亞太地區（中國、日本、印度和亞太地區其他地區）和世界其他地區的全球存在情況對市場進行了分析。到 2023 年，北美將佔據大部分市場佔有率。影響北美抗生素抗藥性市場成長的趨勢是市場成長率以及醫療保健提供者和全體民眾對抗生素抗藥性作為主要威脅的認識。該地區強大的衛生系統促進了創新抗生素和其他技術和診斷工具的開發，以便及早發現和識別抗藥性菌株。此外，美國政府啟動的 "應對抗生素抗藥性國家行動計畫" 也促使公共衛生機構、製藥公司和學術機構之間的資金投入增加。醫療機構高抗生素管理計畫也正在加強尋找對抗抗藥性細菌的方法。例如，開發新型抗感染療法的先驅企業Entasis，以及在重症監護和醫院環境藥物商業化方面擁有良好業績記錄的拉霍亞製藥公司（La Jolla）。 Innoviva 於 2022 年完成了對 Entasis 和 La Jolla 的收購。因此，北美將在 2023 年佔據很大佔有率。

在市場上營運的主要公司包括Pfizer Inc.; Orchid Chemicals & Pharmaceuticals Limited; Melinta Therapeutics, LLC; Innoviva Specialty Therapeutics; Basilea Pharmaceutica Ltd; Wockhardt Limited; Paratek Pharmaceuticals, Inc.; Seres Therapeutics, Inc.; Cipla; Merck & Co. Inc.處於。

目錄

第1章 市場簡介

  • 市場定義
  • 主要目的
  • 相關利益者
  • 限制事項

第2章 調查手法或前提條件

  • 調查流程
  • 調查手法
  • 受訪者簡介

第3章 摘要整理

  • 產業摘要
  • 各市場區隔預測
    • 市場成長的強度
  • 地區展望

第4章 市場動態

  • 促進因素
  • 機會
  • 阻礙因素
  • 趨勢
  • PESTEL分析
  • 需求面分析
  • 供給方面分析
    • 合併和收購
    • 投資Scenario
    • 產業考察:大Start-Ups企業及其獨特策略

第5章 價格分析

  • 各地區價格分析
  • 價格的影響因素

第6章 全球抗生素抗性市場收益 , 2022-2032年

第7章 市場洞察:各疾病類型

  • 泌尿道感染
  • 腹腔內感染疾病
  • 血流感染疾病
  • 難辨梭狀芽孢桿菌傳染病
  • 其他

第8章 市場洞察:病原體類別

  • 鮑氏靜止桿菌
  • 綠色膿菌
  • 黃色葡萄球菌
  • 肺炎球菌
  • 其他

第9章 市場洞察:各類藥物

  • Oxazolidinone
  • ripogurikopepuchido
  • 四環黴素
  • 其他

第10章 市場洞察:各地區

  • 北美
    • 美國
    • 加拿大
    • 其他北美地區
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他歐洲地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太地區
  • 全球其他地區

第11章 價值鏈分析

  • 市場參與企業一覽

第12章 競爭情形

  • 競爭儀表板
  • 競爭市場定位分析
  • 波特的五力分析

第13章 企業簡介

  • Pfizer Inc.
    • Company Overview
    • Key Financials
    • SWOT Analysis
    • Product Portfolio
    • Recent Developments
  • Orchid Chemicals & Pharmaceuticals Limited
  • Melinta Therapeutics, LLC
  • Innoviva Specialty Therapeutics
  • Basilea Pharmaceutica Ltd
  • Wockhardt Limited
  • Paratek Pharmaceuticals, Inc.
  • Seres Therapeutics, Inc.
  • Cipla
  • Merck & Co. Inc.

第14章 縮寫與前提條件

第15章 附錄

簡介目錄
Product Code: UMHE213048

Antimicrobial resistance is a very sensitive and evolving threat within the healthcare market and is indicated by the emergence of multidrug-resistant organisms, to which standard antibiotics are ineffective. These increased rates have made treatment failures become more common, lengths of stay rise, and costs skyrocket, all of which have created the need for new approaches that will address the issues. Industry is keen on investing in the development of new antibiotics and other therapies, and in diagnostics tools because of the high threat level of resistant infections in patients. Other opportunities are related to the geographical areas of diagnostics advances and international partnerships that call for an active strategy to fight antibiotic resistance. In conclusion, there is great potential within the market as key players are aware that increased awareness for practical solutions to reducing the burden of antibiotic resistance on the population is needed.

The Antibiotic Resistance Market is expected to grow at a steady rate of around 5.4% owing to the rising research & development activities. For instance, in November 2022, the Antimicrobial Resistance Multi-Stakeholder Partnership Platform was launched to ensure the growing threats and impacts of antimicrobial resistance are addressed globally. The Food and Agriculture Organization of the United Nations (FAO), the United Nations Environment Programme (UNEP), the World Health Organization (WHO), and the World Organization for Animal Health (WOAH), known as the Quadripartite are joining forces on this initiative to underscore the threat antimicrobial resistance presents to humans, animals, plants, ecosystems, and livelihoods. Moreover, increasing cases of antibiotic-resistant infections and increasing investment in antibiotic research and development activities boost the antibiotic resistance market.

Based on the disease type, the market is segmented into urinary tract infections, intra-abdominal infections, bloodstream infections, clostridium difficile infections, and others. The urinary tract infections (UTIs) segment held a significant share of the market in the year 2023 owing to increased incidence of UTIs especially among females, elder people, and those with chronic diseases. As the frequency of antibiotic-resistant strains like Escherichia coli rises, traditional treatments are becoming less effective and the market for new antibiotics as well as other forms of therapy is growing rapidly. Since these infections are difficult to manage by most healthcare providers, more focus is being placed on the development of specific treatments, diagnostics, and preventive measures. Furthermore, an increased realization of antibiotic resistance consequences has boosted efforts and funding towards UTI-tailored treatments. This segment is expected to see a lot of activities from the stakeholders as there is a need to come up with effective treatment for the condition and come up with intensified management measures towards combating the increased cases of resistance in antibiotic use; especially in UTIs.

Based on the pathogen type, the market is segmented into Acinetobacter baumannii, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pneumoniae, and others. The Staphylococcus aureus segment is expected to experience significant growth in the forecast period owing to infections by methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-sensitive strains, which are becoming resistant to other antibiotic classes. S. aureus is a pathogen that is recognized to cause diverse healthcare-associated and community-acquired skin infections, pneumonia, bacteremia, and other infections that urge the need for effective treatment. The new form of resistance requires the drug companies to develop new antibiotics targeting resistant bacteria, and new treatments including monoclonal antibodies and bacteriophage therapies. Thus, the Staphylococcus aureus segment is expected to grow at a significant rate in the forecast period among the pathogen type.

Based on the drug class, the market is segmented into oxazolidinones, lipoglycopeptides, tetracyclines, and others. The oxazolidinones segment is expected to experience significant growth in the forecast period owing to rising instances of multidrug-resistant Gram-positive infections especially, methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). Among the oxazolidinones, linezolid and tedizolid have become valuable therapeutic agents for managing these hard-to-treat infections owing to the new pathway through which bacterial protein synthesis is blocked. Due to the increased resistance to conventional antibiotics, the global market for new-generation antibiotics such as oxazolidinones is being introduced. In addition, the increased number of applications of these agents in clinical settings together with continuous efforts into the development of new oxazolidinone compounds also put thrust on this market. The oxazolidinones market has the potential to ensure that users get effective treatments for resistant infections and it thus plays an essential role in treating antibiotic resistance and maximizing patient health in healthcare organizations. Thus, the oxazolidinones segment is expected to grow at a significant rate in the forecast period among the drug class.

For a better understanding of the market adoption of antibiotic resistance, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America held the majority share of the market in the year 2023. The trends influencing the antibiotic resistance market growth in North America are the growing rate of the market and the recognition of antibiotic resistance as a significant threat among healthcare providers and the overall population. The strong health system of the region enables the development of innovative antibiotics and other technologies and diagnostic tools that strive to address and identify resistant strains in the early stages. Further, the launch of the National Action Plan for Combating Antibiotic-Resistant Bacteria by the U.S government increased funding between public health entities, pharmaceuticals, and academic institutions. Healthcare facility-high antibiotic stewardship programs also contribute towards increasing efforts to find ways to counter resistance. For instance, Entasis, a pioneer in the development of novel, anti-infective therapies, and La Jolla Pharmaceutical Company (La Jolla), with proven capabilities in commercializing medicines in critical care and hospital settings. Innoviva completed the acquisitions of Entasis and La Jolla in 2022. Thus, amongst areas, North America held a significant share of the market in the year 2023.

Some of the major players operating in the market include Pfizer Inc.; Orchid Chemicals & Pharmaceuticals Limited; Melinta Therapeutics, LLC; Innoviva Specialty Therapeutics; Basilea Pharmaceutica Ltd; Wockhardt Limited; Paratek Pharmaceuticals, Inc.; Seres Therapeutics, Inc.; Cipla; Merck & Co. Inc.

TABLE OF CONTENTS

1.MARKET INTRODUCTION

  • 1.1. Market Definitions
  • 1.2. Main Objective
  • 1.3. Stakeholders
  • 1.4. Limitation

2.RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1. Research Process of the Antibiotic Resistance Market
  • 2.2. Research Methodology of the Antibiotic Resistance Market
  • 2.3. Respondent Profile

3.EXECUTIVE SUMMARY

  • 3.1. Industry Synopsis
  • 3.2. Segmental Outlook
    • 3.2.1. Market Growth Intensity
  • 3.3. Regional Outlook

4.MARKET DYNAMICS

  • 4.1. Drivers
  • 4.2. Opportunity
  • 4.3. Restraints
  • 4.4. Trends
  • 4.5. PESTEL Analysis
  • 4.6. Demand Side Analysis
  • 4.7. Supply Side Analysis
    • 4.7.1. Merger & Acquisition
    • 4.7.2. Investment Scenario
    • 4.7.3. Industry Insights: Leading Startups and Their Unique Strategies

5.PRICING ANALYSIS

  • 5.1. Regional Pricing Analysis
  • 5.2. Price Influencing Factors

6.GLOBAL ANTIBIOTIC RESISTANCE MARKET REVENUE (USD BN), 2022-2032F

7.MARKET INSIGHTS BY DISEASE TYPE

  • 7.1. Urinary Tract Infection
  • 7.2. Intra-Abdominal Infections
  • 7.3. Blood Stream Infections
  • 7.4. Clostridium Difficile Infections
  • 7.5. Others

8.MARKET INSIGHTS BY PATHOGEN TYPE

  • 8.1. Acinetobacter Baumannii
  • 8.2. Pseudomonas Aeruginosa
  • 8.3. Staphylococcus Aureus
  • 8.4. Streptococcus Pneumoniae
  • 8.5. Others

9.MARKET INSIGHTS BY DRUG CLASS

  • 9.1. Oxazolidinones
  • 9.2. Lipoglycopeptides
  • 9.3. Tetracyclines
  • 9.4. Others

10.MARKET INSIGHTS BY REGION

  • 10.1. North America
    • 10.1.1. U.S.
    • 10.1.2. Canada
    • 10.1.3. Rest of North America
  • 10.2. Europe
    • 10.2.1. Germany
    • 10.2.2. U.K.
    • 10.2.3. France
    • 10.2.4. Italy
    • 10.2.5. Spain
    • 10.2.6. Rest of Europe
  • 10.3. Asia-Pacific
    • 10.3.1. China
    • 10.3.2. Japan
    • 10.3.3. India
    • 10.3.4. Rest of Asia-Pacific
  • 10.4. Rest of World

11.VALUE CHAIN ANALYSIS

  • 11.1. List of Market Participants

12.COMPETITIVE LANDSCAPE

  • 12.1. Competition Dashboard
  • 12.2. Competitor Market Positioning Analysis
  • 12.3. Porter Five Forces Analysis

13.COMPANY PROFILES

  • 13.1. Pfizer Inc.
    • 13.1.1. Company Overview
    • 13.1.2. Key Financials
    • 13.1.3. SWOT Analysis
    • 13.1.4. Product Portfolio
    • 13.1.5. Recent Developments
  • 13.2. Orchid Chemicals & Pharmaceuticals Limited
  • 13.3. Melinta Therapeutics, LLC
  • 13.4. Innoviva Specialty Therapeutics
  • 13.5. Basilea Pharmaceutica Ltd
  • 13.6. Wockhardt Limited
  • 13.7. Paratek Pharmaceuticals, Inc.
  • 13.8. Seres Therapeutics, Inc.
  • 13.9. Cipla
  • 13.10. Merck & Co. Inc.

14.ACRONYMS & ASSUMPTION

15.ANNEXURE